Skip to content
weblogo
  • Studies
  • Contribute
  • News
  • Publications
  • About
  • Studies
  • Contribute
  • News
  • Publications
  • About
Search

Tag: Switzerland

Initial characterisation of ELISA assays and the immune response of the clinically correlated SARS-CoV-2 biobank SERO-BL-COVID-19 collected during the pandemic onset in Switzerland

To accurately measure seroprevalance in the population, boththe expected immune response as well as the assay performances have to be well characterised.

Read More »
7. July 2020

Serology-informed estimates of SARS-COV-2 infection fatality risk in Geneva, Switzerland

The infection fatality risk (IFR) is the average number of deaths per infection by a pathogen and is key to characterizing the severity of infection across the population and for specific demographic groups.

Read More »
12. June 2020

Repeated seroprevalence of anti-SARS-CoV-2 IgG antibodies in a population-based sample from Geneva, Switzerland

Assessing the burden of COVID-19 based on medically-attended case counts is suboptimal given its reliance on testing strategy, changing case definitions and the wide spectrum of disease presentation

Read More »
6. May 2020
weblogo

Plattform for seroprevalence studies on SARS-COV-2

  • Privacy Policy
  • Impress

© 2023 HELMHOLTZ-ZENTRUM FÜR INFEKTIONSFORSCHUNG GMBH - All rights reserved